Affects 1m in US Leading cause of vision loss in people under 65 Laser therapy (burns to retina) limited efficacy No FDA approved drug treatments US Market estimated $1.5-4B
Iluvien (DME) Status
Phase III clinical trials in approx. 1,000 patients NDA given Priority Review Received CRL December 2010 Positive 36 month data released in Feb, subgroup analysis in May Resubmitted May 2011 Potential approval in Q4 2011
$25 million milestone due on FDA approval pSivida receives 20% of ILUVIEN profits
Simple. PSDV offers a delivery method. Any drug, protein etc, could be used for a specific indication. If PSDV gets another approved platform (they have two) all drug companies have an eye on it. Look into their pipeline platforms. ALIM is just one company with one drug for one indication. ALIM owns the car, PSDV owns the freeway.